HOME >> BIOLOGY >> NEWS
Leading cloning experts challenge Clonaid to prove claim

PITTSBURGH, Jan. 6 In reaction to the recent claim by Clonaid that it had produced the first human clone, three international cloning experts emphasized that current cloning techniques have been shown to seriously compromise the health of cloned offspring. Randall Prather, distinguished professor of reproductive biotechnology at the University of Missouri-Columbia; Ian Wilmut, an embryologist at the Roslin Institute near Edinburgh, Scotland; and Gerald Schatten, professor and vice-chair of obstetrics, gynecology & reproductive sciences and cell biology-physiology at the University of Pittsburgh School of Medicine; said that it was highly likely that cloned children would suffer similar problems with their health and this alone should deter scientists from cloning human beings.

"All of the reports from cloning experiments describe a high incidence of late abortion or the birth of dead animals," Prather said. "When live cloned offspring have been produced, many have been subject to abnormalities that were apparent only after birth. These abnormalities include premature death at many different ages, respiratory failure, absence of an immune response and inadequate kidney function. These problems are believed to be a consequence of inappropriate gene expression resulting from incomplete 'reprogramming' of the adult cell used in cloning. There is absolutely no reason to expect the situation to be different in humans. Furthermore, human brain development is far more complex than in animals and the neuropsychiatric consequences for cloned children might be devastating. Until there is compelling and scientifically validated evidence that the situation is different in human embryos it is grossly irresponsible to attempt to clone children."

Wilmut, Schatten and Prather also strongly support independent tests by a respected authority, such as the National Academy of Sciences, to confirm that the DNA of Eve, the baby Clonaid claims is the first human clone, i
'"/>

Contact: Michele Baum
412-647-3555
University of Pittsburgh Medical Center
6-Jan-2003


Page: 1 2

Related biology news :

1. Leading scientists design new framework for biodiversity conservation
2. Leading science, higher-education and engineering groups urge six improvements to U.S. visa quagmire
3. Leading experts in field of gene therapy to meet in Minneapolis
4. Leading U.S. gun manufacturer joins NJIT to develop personalized handgun
5. Leading bacterial pathogen is sequenced
6. Leading cancer research organization urges FDA to speed approval of drugs for precancers
7. Leading lab expert to update medical community on diagnostic testing for thyroid function
8. Leading indoor environment experts to convene at Syracuse University to discuss air quality and urban environments
9. Leading snake expert dies at 38
10. Leading experts address safety and economics of biotech crops
11. Taking the show on the road - Leading researchers to conduct hands-on science symposium for 500 San Francisco area high school students

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Leading cloning experts challenge Clonaid prove claim

(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: